心脏替代治疗在心源性休克患者中的轨迹与结局
基于CSWG注册(2021-2024)7,750例心源性休克患者,1,187例(15.3%)接受心脏替代治疗(HRT)。HRT组更年轻、心衰相关CS更多、合并症更少、SCAI E期和表型III更少,死亡率更低(6.2% vs 34.1%)。倾向评分匹配后HRT与生存改善相关(OR 0.11,95%CI 0.08-0.16,p<0.001),并发症预测死亡(OR 2.0,95%CI 1.81-2.21,p<0.001)。
要点
- HRT组死亡率6.2%,显著低于无HRT组的34.1%。
- 匹配后HRT与生存改善独立相关(OR 0.11,95%CI 0.08-0.16)。
- 并发症是死亡预测因素(OR 2.0,95%CI 1.81-2.21)。
核心结论
- 接受HRT的CS患者SCAI E期和表型III更少、COMRI-CS风险更低,尽管并发症更多但死亡率更低。
- 匹配后HRT与生存改善相关,并发症预测死亡,仍需 robust 风险预测因子。
研究设计与样本
- 回顾性分析CSWG注册(2021-2024),共7,750例CS患者,1,187例(15.3%)接受HRT。
- CS严重程度采用CSWG的SCAI分期、机器学习衍生表型和COMRI-CS评估。
- 采用倾向评分匹配(3:1无HRT:HRT)比较结局。
主要发现
- HRT组更年轻(57[47-65] vs 64[54-73]岁,p<0.001),心衰相关CS更多(84.9% vs 55.8%,p<0.001)。
- HRT组SCAI A期18.1% vs 11.4%、C期14.3% vs 8.1%、D期44.5% vs 35.9%,B期14.7% vs 16.9%、E期8.4% vs 27.7%(均p<0.001)。
- HRT组合并症更少:高COMRI-CS风险2.8% vs 5.8%,极高风险0% vs 0.9%;表型III 7.3% vs 21.4%(均p<0.001)。
- HRT组死亡率6.2% vs 34.1%(p<0.001),但并发症率更高。
- 匹配后HRT与生存改善相关(OR 0.11,95%CI 0.08-0.16,p<0.001),并发症预测死亡(OR 2.0,95%CI 1.81-2.21,p<0.001)。
临床怎么用
- 对CS患者评估HRT时需综合SCAI分期、表型和合并症风险,HRT可能改善生存但需警惕并发症。
局限性
- 回顾性注册研究,存在选择偏倚和未测量混杂。
- HRT组并发症率更高,可能影响结局解释。
- 需更稳健的HRT后结局风险预测因子。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Data describing trajectories of cardiogenic shock (CS) patients undergoing heart replacement therapies (HRT) remain limited. We aimed to compare CS patients receiving HRT vs none during index CS hospitalization. METHODS: We retrospectively analyzed the Cardiogenic Shock Working Group (CSWG) registry (2021-2024). CS severity was characterized using CSWG definitions of Society for Cardiovascular Angiography and Interventions (SCAI) stages, machine learning-derived phenotypes, and the Comorbidity Risk Index for CS (COMRI-CS). RESULTS: Among 7,750 patients, 1,187 (15.3%) received HRT. Compared with the no-HRT cohort, HRT recipients were younger (57 [47-65] vs 64 [54-73] years, p < 0.001) and more likely to have heart failure-related CS (84.9% vs 55.8%, p < 0.001). They had more baseline CSWG-SCAI stages A (18.1% vs 11.4%), C (14.3% vs 8.1%), and D (44.5% vs 35.9%), but less stages B (14.7% vs 16.9%) and E (8.4% vs 27.7%; all p < 0.001). They had fewer comorbidities (high COMRI-CS risk: 2.8% vs 5.8%, very high risk: 0% vs 0.9%), fewer phenotype III (7.3% vs 21.4%), and lower mortality (6.2% vs 34.1%, all p < 0.001), despite higher complication rates. In a propensity score-matched cohort (3 no-HRT:1 HRT), HRT was associated with improved survival (OR 0.11, 95% CI 0.08-0.16, p < 0.001), whereas complications predicted death (OR 2.0, 95% CI 1.81-2.21, p < 0.001). CONCLUSION: CS patients receiving HRT exhibited less SCAI stage E and phenotype III, more favorable COMRI-CS profiles, and lower mortality despite higher complication rates. Robust risk predictors for post-HRT outcomes in CS are needed.
引用
- Ton VK, Kong Q, Kanwar MK, et al. Trajectories and outcomes in patients with cardiogenic shock receiving heart replacement therapies. J Heart Lung Transplant. 2026. PMID: 41951134. doi:10.1016/j.healun.2026.03.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。